aganirsen
Nucleic acidexperimental
Aganirsen is a 25-mer DNA antisense oligonucleotide therapeutic inhibiting insulin receptor substrate-1 (IRS-1), which is being investigated as a topical treatment for ocular neovascularization. Aganirsen is a candidate for the treatment of ocular neovascularization in patients with front of the eye (cornea) or back of the eye (retinal) diseases, including progressive corneal neovascularization in patients with infectious keratitis and wet age related macular degeneration (AMD). — Wikipedia
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT02947867)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Insulin receptor substrate 1ANTISENSE INHIBITOR
IRS1 antisense inhibitor
- Insulin receptor substrate 1 mRNAANTISENSE INHIBITOR
Insulin receptor substrate 1 mRNA antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAganirsen ↗
- ChEMBLCHEMBL2108296 ↗
Also known as
- aganirsen
- aganirsen
- aganirsen
- gs 101
- gs-101
- gs101 antisense oligonucleotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02947867 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2017 | Gene Signal SAS, Johannes Gutenburg University, University of Cologne, University of London |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gene Signal SAS | For profit | 1 | 1 | 1 | 2017 |
| Johannes Gutenburg University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Cologne | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1